Top

Osteoporosis International

Published in:

01-12-2021 | Bisphosphonate | Review

Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis

Authors: L. dos Santos Ferreira, L. G. Abreu, C. B. Calderipe, M. D. Martins, L. F. Schuch, A. C. U. Vasconcelos

Published in: Osteoporosis International | Issue 12/2021

Abstract

Summary

Considering the lack of studies determining the real TPTD efficacy in individuals who develop MRONJ, our objective was to combine the available data on MRONJ cases treated with TPTD. The findings demonstrated that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ.

Purpose

To integrate the data published on the effect of teriparatide (TPTD) therapy on cases of medication-related osteonecrosis of the jaws (MRONJ) into a comprehensive analysis of clinical features.

Methods

An electronic search was undertaken in six databases. Descriptive analyses of clinicodemographic data of MRONJ were carried out. Poisson regression was also run to evaluate predictors of total resolution of MRONJ treated with TPTD.

Results

Twenty-six publications comprising 111 cases were included. Most reported cases affected female individuals (82.0%) with a mean age of 76.54 years. Osteoporosis (76.5%) represented the main reason for using antiresorptive drugs, with bisphosphonates (98.1%) as the most frequently reported. Comorbidities were commonly present. The most related trigger factor of MRONJ was dental extraction (61.7%). Mandible (75.8%) was the most commonly affected site, with a mean evolution time of 5 months. MRONJ stage 2 (61.3%) was the most prevalent. Regarding TPTD treatment, in 45.1% cases, TPTD was used alone, with the total resolution being observed in 59.5% of the individuals. Associated therapy (54.9%) included surgery, antibiotic therapy, and laser therapy. Mean follow-up was 8.7 months. Poisson regression demonstrated that individuals with MRONJ stage 1 were 1.21 times more likely to present total resolution of osteonecrosis than individuals with MRONJ stage 3 (CI = 1.02–1.43; p < 0.023). Individuals who had undergone treatment with TPTD in association with another therapeutic modality were 1.21 times more likely to present total resolution of osteonecrosis than those who had undergone treatment with TPTD alone (CI = 1.40–1.39; p < 0.010).

Conclusion

TPTD in combination with another therapy, especially antibiotic therapy, should be considered an effective therapeutic modality for MRONJ.

Available only for authorised users

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaws–2014 update. J Oral Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031CrossRefPubMed

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 20:8–24. https://doi.org/10.1016/j.jocd.2016.09.005CrossRefPubMed

Migliorati CA, Brennan MT, Peterson DE (2019) Medication-related osteonecrosis of the jaws. J Natl Cancer Inst Monogr 1:53. https://doi.org/10.1093/jncimonographs/lgz009CrossRef

Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, Brennan MT (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 18–8:1099–1106. https://doi.org/10.1007/s00520-010-0882-1CrossRef

Yamada SI, Kurita H, Kondo E, Suzuki S, Nishimaki F, Yoshimura N, Morioka M, Ishii S, Kamata T (2019) Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. Clin Oral Investig 23–8:3203–3211. https://doi.org/10.1007/s00784-018-2743-0CrossRef

Eastell R, Walsh JS (2017) Anabolic treatment for osteoporosis: teriparatide. Clin Cases Miner Bone Metab 14:173–178. https://doi.org/10.11138/ccmbm/2017.14.1.173CrossRefPubMedPubMedCentral

Cheng C, Wentworth K, Shoback DM (2019) New frontiers in osteoporosis therapy. Annu Rev Med 71:277–288. https://doi.org/10.1146/annurev-med-052218-020620CrossRefPubMed

Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Hjelle CP, Siddique M et al (2020) Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol 10(38):2971–2980. https://doi.org/10.1200/JCO.19.02192CrossRef

Page MJ, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow CD et al (2020). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv. https://doi.org/10.31222/osf.io/v7gm2

10.

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, CARE Group (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med 2:38–43. https://doi.org/10.7453/gahmj.2013.008CrossRefPubMedPubMedCentral

11.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366. https://doi.org/10.1136/bmj.l4898

12.

Ohbayashi Y, Iwasaki A, Nakai F, Mashiba T, Miyake M (2020) A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporos Int 31:577–585. https://doi.org/10.1007/s00198-019-05199-wCrossRefPubMed

13.

Hong SO, Lee CY, Jung J, Kim DY, Walter C, Kwon YD (2017) A retrospective study of osteomyelitis and osteonecrosis of the jaws and its etiologic implication of bisphosphonate in Asians. Clin Oral Investig 21(5):1905–1911. https://doi.org/10.1007/s00784-016-1973-2CrossRefPubMed

14.

Petrovic M, Jelovac DB, Antic S, Antunovic M, Lukic N, Sabani M et al (2019) Medication-related osteonecrosis of the jaws: two center retrospective cohort studies. BioMed Res Int 8345309. https://doi.org/10.1155/2019/8345309

15.

Martins AS, Correia JA, Salvado F, Caldas C, Santos N, Capelo A, Palmela P (2017) Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - a retrospective cohort study. J Craniomaxillofac Surg 45:1736–1742. https://doi.org/10.1016/j.jcms.2017.07.014CrossRefPubMed

16.

McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 24:527–536. https://doi.org/10.1111/odi.12708CrossRefPubMed

17.

Kanis JA (2007) Assessment of osteoporosis at the primary health‐care level. Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases, 66.

18.

Kanwar N, Bakr MM, Meer M, Siddiqi A (2020) Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. Br Dent J 228:886–892. https://doi.org/10.1038/s41415-020-1642-3CrossRefPubMed

19.

Kunchur R, Need A, Hughes T (2009) Clinical investigation of C terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167–1173CrossRef

20.

Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932. https://doi.org/10.1111/jcpe.12455CrossRefPubMed

21.

Vall H, Parmar M (2020) Teriparatide. StatPearls [Internet] Available from: https://www.ncbi.nlm.nih.gov/books/NBK559248/. Accessed 10 Jan 2021.

22.

Kwon YD, Kim DY (2016) Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent J 4:41. https://doi.org/10.3390/dj4040041CrossRef

23.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 19 386(9999):1147–55. https://doi.org/10.1016/S0140-6736(15)61120-5CrossRef

24.

FDA. (2009) Teriparatide. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021318s012lbl.pdf/ . Accessed 25 Apr 2021.

25.

OCEBM Levels of Evidence Working Group*. “The Oxford levels of evidence 2”. Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence Accessed 25 Apr 2021.

Title: Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis
Authors: L. dos Santos Ferreira
L. G. Abreu
C. B. Calderipe
M. D. Martins
L. F. Schuch
A. C. U. Vasconcelos
Publication date: 01-12-2021
Publisher: Springer London
Keywords: Bisphosphonate
Osteonecrosis
Denosumab
Denosumab
Published in: Osteoporosis International / Issue 12/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-021-06078-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis

Abstract

Summary

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

“Fear of falling serves as protection and signifies potential danger”: a qualitative study to conceptualise the phrase “fear of falling” in women with osteoporosis

Comment on “Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies”

Comparison of fracture risk between type 1 and type 2 diabetes: a comprehensive real-world data

Excess mortality after hip fracture: fracture or pre-fall comorbidity?

Polymorphic variants of alkaline phosphatase gene correlate with clinical signs of adult hypophosphatasia?

Risk factors for hip fracture